Thermo Fisher Scientific Buys Viral Vector Manufacturing Business From Novasep for About $880 Million

By Dave Sebastian

Thermo Fisher Scientific Inc. has bought Henogen SA, Groupe Novasep SAS' viral vector manufacturing business in Belgium, for about 725 million euros ($879.7 million) in cash, an acquisition it said would help its capabilities for gene vaccines and therapies.

The business, which has about 400 employees, provides contract-manufacturing services for vaccines and therapies to biotechnology companies and biopharma customers. It had an estimated 2020 revenue of EUR80 million ($97 million), the companies said.

The business will be part of Thermo Fisher Scientific's pharma services business under the laboratory products and services segment, it said.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

January 15, 2021 06:56 ET (11:56 GMT)

Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Mar 2024 to Apr 2024